새롭게 진단받은 만성기 만성 골수성 백혈병 환자에서 nilotinib 400 mg을 하루 두 번 복용한 2상 시험의 장기 결과

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia2015 · 41 citations
2. 2Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl2005 · 1,483 citations
3. 3The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events2018 · 250 citations
4. 4Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial2016 · 850 citations
5. 5Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up2012 · 440 citations